ASX health April winners: Sector rises 2pc in stronger month for markets
The S&P/ASX 200 healthcare index rose 2.16% in April, as the local market showed resilience to geopolitical and economics headwinds.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6%
Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months
Several approvals during April, including for EBR and Orthocell, helped boost sentiment in the sector
The S&P/ASX 200 Health Care Index was stronger in April, rising 2.16% after being the second-worst performing sector in March.
Healthcare followed the broader market upward with the S&P/ASX 200 rallying 3.6% in April as the local bourse held firm against ongoing global geopolitical tensions and economic headwinds.
Morgans healthcare analyst Iain Wilkie told Stockhead April was a marked improvement on recent months, partly due to US President Donald Trump softening his stance on tariffs late in April and easing tensions around a potential trade war with China.
Wilkie said April marked a solid month of regulatory approvals with EBR Systems (ASX:EBR) gaining US FDA approval for its WISE CRT system – the world’s first and only wireless solution for pacing the left side of the heart.
Orthocell (ASX:OCC) scored a hattrick of three regulatory approvals in April for its flagship nerve repair product Remplir, including in Canada, Thailand and the US markets.
The latest approvals add to pre-existing approvals for Remplir in Australia, New Zealand and Singapore, equating to a significant total addressable market of US$1.8 billion. Regulatory applications for the EU and UK are on track to be submitted in the next six to 12 months.
Wilkie said the approvals were also reassuring amid concerns about recent changes at the FDA with reported mass layoffs under Tesla CEO and billionaire Elon Musk’s Department of Government Efficiency (DOGE), which were quickly followed by a partial rehiring.
"It's good momentum for the sector and shows approvals are still getting through the FDA in time," Wilkie said.
"We will see what happens in the next few months."
How ASX biotechs performed in April
| CODE | COMPANY | PRICE | 1 MONTH RETURN % | MARKET CAP |
|---|---|---|---|---|
| ICR | Intelicare Holdings | $ 0.01 | 66.7% | 4 |
| NSB | Neuroscientific | $ 0.05 | 35.1% | 7 |
| AVR | Anteris Technologies | $ 8.55 | 31.5% | 270 |
| CC5 | Clever Culture | $ 0.02 | 28.6% | 30 |
| SHG | Singular Health | $ 0.30 | 22.9% | 77 |
| CHM | Chimeric Therapeutic | $ 0.01 | 20.0% | 14 |
| IXC | Invex Ther | $ 0.08 | 19.1% | 6 |
| 4DX | 4Dmedical Limited | $ 0.32 | 18.5% | 135 |
| IMR | Imricor Med Sys | $ 1.62 | 17.4% | 476 |
| COV | Cleo Diagnostics | $ 0.41 | 17.1% | 52 |
| DVL | Dorsavi Ltd | $ 0.01 | 16.7% | 5 |
| DXB | Dimerix Ltd | $ 0.48 | 15.7% | 425 |
| IDT | IDT Australia Ltd | $ 0.12 | 15.0% | 49 |
| PME | Pro Medicus Limited | $ 229.41 | 14.8% | 24,998 |
| AVH | Avita Medical | $ 3.10 | 14.0% | 369 |
| LDX | Lumos Diagnostics | $ 0.03 | 12.5% | 21 |
| PGC | Paragon Care Limited | $ 0.42 | 12.0% | 712 |
| EYE | Nova EYE Medical Ltd | $ 0.11 | 10.0% | 31 |
| 1AI | Algorae Pharma | $ 0.01 | 9.1% | 10 |
| ECS | ECS Botanics Holding | $ 0.01 | 8.3% | 16 |
| MVP | Medical Developments | $ 0.60 | 8.1% | 71 |
| AHX | Apiam Animal Health | $ 0.41 | 8.0% | 79 |
| ALA | Arovella Therapeutic | $ 0.09 | 7.5% | 103 |
| OCC | Orthocell Limited | $ 1.60 | 6.7% | 391 |
| AT1 | Atomo Diagnostics | $ 0.02 | 5.9% | 13 |
| PNV | Polynovo Limited | $ 1.21 | 5.7% | 888 |
| IDX | Integral Diagnostics | $ 2.42 | 5.7% | 871 |
| NAN | Nanosonics Limited | $ 4.80 | 5.5% | 1,486 |
| CYP | Cynata Therapeutics | $ 0.20 | 5.4% | 44 |
| VBS | Vectus Biosystems | $ 0.08 | 5.3% | 4 |
| RHT | Resonance Health | $ 0.04 | 5.1% | 16 |
| RMD | ResMed Inc. | $ 36.68 | 4.9% | 54,516 |
| ALC | Alcidion Group Ltd | $ 0.09 | 4.9% | 117 |
| SIG | Sigma Health Ltd | $ 3.02 | 4.9% | 35,436 |
| ACL | Au Clinical Labs | $ 3.12 | 4.7% | 621 |
| COH | Cochlear Limited | $ 274.59 | 4.7% | 17,937 |
| OCA | Oceania Healthc Ltd | $ 0.57 | 4.6% | 424 |
| HLS | Healius | $ 1.46 | 4.3% | 1,106 |
| CU6 | Clarity Pharma | $ 2.20 | 4.3% | 850 |
| FPH | Fisher & Paykel H. | $ 31.51 | 4.2% | 19,006 |
| SNZ | Summerset Grp Hldgs | $ 10.55 | 4.1% | 2,537 |
| TRU | Truscreen | $ 0.03 | 3.7% | 16 |
| ARX | Aroa Biosurgery | $ 0.44 | 3.5% | 159 |
| TLX | Telix Pharmaceutical | $ 27.13 | 2.3% | 9,853 |
| AFP | Aft Pharmaceuticals | $ 2.34 | 1.7% | 245 |
| CYC | Cyclopharm Limited | $ 1.17 | 1.7% | 133 |
| SHL | Sonic Healthcare | $ 26.08 | 1.2% | 12,538 |
| CSL | CSL Limited | $ 251.13 | 0.7% | 123,518 |
| REG | Regis Healthcare Ltd | $ 6.81 | 0.7% | 2,208 |
| PCK | Painchek Ltd | $ 0.04 | 0.0% | 66 |
| SPL | Starpharma Holdings | $ 0.09 | 0.0% | 38 |
| AVE | Avecho Biotech Ltd | $ 0.01 | 0.0% | 16 |
| VFX | Visionflex Group Ltd | $ 0.00 | 0.0% | 10 |
| ACR | Acrux Limited | $ 0.02 | 0.0% | 9 |
| EPN | Epsilon Healthcare | $ 0.02 | 0.0% | 8 |
| IVX | Invion Ltd | $ 0.10 | 0.0% | 8 |
| PAB | Patrys Limited | $ 0.00 | 0.0% | 5 |
| TD1 | Tali Digital Limited | $ 0.00 | 0.0% | 3 |
| OSX | Osteopore Limited | $ 0.02 | 0.0% | 3 |
| IMC | Immuron Limited | $ 0.07 | -0.7% | 15 |
| CUV | Clinuvel Pharmaceut. | $ 11.36 | -0.9% | 580 |
| BOT | Botanix Pharma Ltd | $ 0.45 | -1.1% | 904 |
| EBO | Ebos Group Ltd | $ 34.20 | -1.2% | 7,017 |
| NOX | Noxopharm Limited | $ 0.08 | -1.2% | 22 |
| M7T | Mach7 Tech Limited | $ 0.34 | -1.5% | 84 |
| ONE | Oneview Healthcare | $ 0.29 | -1.7% | 216 |
| RAC | Race Oncology Ltd | $ 1.05 | -1.9% | 212 |
| CTE | Cryosite Limited | $ 0.78 | -1.9% | 38 |
| PTX | Prescient Ltd | $ 0.05 | -2.1% | 38 |
| NEU | Neuren Pharmaceut. | $ 11.66 | -2.3% | 1,573 |
| SDI | SDI Limited | $ 0.84 | -2.3% | 100 |
| RHC | Ramsay Health Care | $ 33.26 | -2.5% | 7,860 |
| VHL | Vitasora Health Ltd | $ 0.04 | -2.6% | 60 |
| MYX | Mayne Pharma Ltd | $ 7.03 | -2.8% | 571 |
| ILA | Island Pharma | $ 0.16 | -3.0% | 38 |
| MX1 | Micro-X Limited | $ 0.06 | -3.2% | 37 |
| IMM | Immutep Ltd | $ 0.27 | -3.6% | 394 |
| OIL | Optiscan Imaging | $ 0.14 | -3.6% | 113 |
| PYC | PYC Therapeutics | $ 1.18 | -3.7% | 714 |
| IRX | Inhalerx Limited | $ 0.03 | -3.8% | 5 |
| CGS | Cogstate Ltd | $ 1.33 | -4.3% | 227 |
| VLS | Vita Life Sciences.. | $ 1.82 | -4.5% | 99 |
| AGH | Althea Group | $ 0.02 | -4.5% | 19 |
| AHC | Austco Healthcare | $ 0.28 | -5.1% | 100 |
| TRJ | Trajan Group Holding | $ 0.81 | -5.3% | 128 |
| HMD | Heramed Limited | $ 0.02 | -5.3% | 15 |
| EMV | Emvision Medical | $ 1.96 | -6.2% | 164 |
| NYR | Nyrada Inc. | $ 0.10 | -7.0% | 23 |
| TRI | Trivarx Ltd | $ 0.01 | -7.1% | 7 |
| IPD | Impedimed Limited | $ 0.04 | -7.3% | 71 |
| NUZ | Neurizon Therapeutic | $ 0.12 | -7.7% | 69 |
| EZZ | EZZ Life Science | $ 1.43 | -7.7% | 65 |
| LGP | Little Green Pharma | $ 0.12 | -8.0% | 36 |
| MSB | Mesoblast Limited | $ 1.80 | -8.4% | 2,367 |
| BMT | Beamtree Holdings | $ 0.22 | -8.5% | 62 |
| PSQ | Pacific Smiles Grp | $ 1.76 | -8.6% | 284 |
| IIQ | Inoviq Ltd | $ 0.37 | -8.6% | 45 |
| NXS | Next Science Limited | $ 0.10 | -9.1% | 26 |
| PER | Percheron | $ 0.01 | -9.1% | 10 |
| EMD | Emyria Limited | $ 0.03 | -9.7% | 15 |
| ANN | Ansell Limited | $ 30.30 | -10.5% | 4,512 |
| ATH | Alterity Therap Ltd | $ 0.01 | -11.1% | 78 |
| OSL | Oncosil Medical | $ 0.00 | -11.1% | 16 |
| CMP | Compumedics Limited | $ 0.31 | -11.6% | 58 |
| AGN | Argenica | $ 0.68 | -11.8% | 93 |
| MDR | Medadvisor Limited | $ 0.10 | -12.7% | 57 |
| PAR | Paradigm Bio. | $ 0.29 | -13.6% | 121 |
| VIT | Vitura Health Ltd | $ 0.07 | -13.8% | 48 |
| TYP | Tryptamine Ltd | $ 0.03 | -13.9% | 45 |
| BIT | Biotron Limited | $ 0.00 | -14.3% | 4 |
| BP8 | Bph Global Ltd | $ 0.00 | -14.3% | 1 |
| IME | Imexhs Limited | $ 0.34 | -15.0% | 17 |
| NC6 | Nanollose Limited | $ 0.03 | -15.0% | 9 |
| ACW | Actinogen Medical | $ 0.03 | -15.6% | 83 |
| DOC | Doctor Care Anywhere | $ 0.08 | -15.8% | 30 |
| UBI | Universal Biosensors | $ 0.06 | -15.9% | 16 |
| AYA | Artryalimited | $ 0.63 | -16.0% | 76 |
| EOF | Ecofibre Limited | $ 0.02 | -16.0% | 7 |
| TRP | Tissue Repair | $ 0.22 | -17.0% | 12 |
| MAP | Microbalifesciences | $ 0.17 | -17.1% | 82 |
| CSX | Cleanspace Holdings | $ 0.39 | -17.2% | 29 |
| ZLD | Zelira Therapeutics | $ 0.38 | -17.4% | 5 |
| LTP | Ltr Pharma Limited | $ 0.38 | -18.5% | 73 |
| RCE | Recce Pharmaceutical | $ 0.29 | -18.7% | 78 |
| IBX | Imagion Biosys Ltd | $ 0.01 | -18.8% | 3 |
| SOM | SomnoMed Limited | $ 0.45 | -18.9% | 95 |
| GSS | Genetic Signatures | $ 0.41 | -19.0% | 110 |
| CVB | Curvebeam Ai Limited | $ 0.10 | -20.0% | 39 |
| CBL | Control Bionics | $ 0.04 | -20.0% | 11 |
| CTQ | Careteq Limited | $ 0.01 | -20.0% | 3 |
| GLH | Global Health Ltd | $ 0.09 | -21.7% | 5 |
| RAD | Radiopharm | $ 0.02 | -22.2% | 51 |
| CDX | Cardiex Limited | $ 0.06 | -22.7% | 23 |
| UCM | Uscom Limited | $ 0.02 | -23.3% | 6 |
| RGT | Argent Biopharma Ltd | $ 0.13 | -23.5% | 8 |
| RHY | Rhythm Biosciences | $ 0.06 | -23.8% | 19 |
| NTI | Neurotech Intl | $ 0.03 | -24.2% | 25 |
| CMB | Cambium Bio Limited | $ 0.23 | -24.6% | 4 |
| BDX | Bcaldiagnostics | $ 0.08 | -24.9% | 30 |
| IMU | Imugene Limited | $ 0.02 | -25.0% | 172 |
| 1AD | Adalta Limited | $ 0.01 | -25.0% | 4 |
| FRE | Firebrickpharma | $ 0.07 | -25.3% | 15 |
| MVF | Monash IVF Group Ltd | $ 0.84 | -26.0% | 334 |
| SNT | Syntara Limited | $ 0.06 | -26.3% | 99 |
| PIQ | Proteomics Int Lab | $ 0.36 | -28.0% | 54 |
| ANR | Anatara Ls Ltd | $ 0.01 | -28.6% | 1 |
| ATX | Amplia Therapeutics | $ 0.05 | -30.0% | 21 |
| EBR | EBR Systems | $ 1.22 | -30.3% | 464 |
| PEB | Pacific Edge | $ 0.08 | -31.8% | 61 |
| HIQ | Hitiq Limited | $ 0.03 | -32.4% | 11 |
| CAN | Cann Group Ltd | $ 0.02 | -36.0% | 10 |
| ADR | Adherium Ltd | $ 0.01 | -36.4% | 5 |
| MEM | Memphasys Ltd | $ 0.01 | -44.4% | 12 |
NeuroScientific Biopharmaceuticals (ASX:NSB) rose 35.1% after sealing a deal to acquire StemSmart, a patented stem cell tech from Isopogen WA, giving it full rights to produce next-generation cell therapies using mesenchymal stromal cells (MSCs).
Early trial results in Crohn’s patients are promising, showing the treatment is safe, effective, and potentially life-changing. To fund the move, NeurosScientific has raised $3.5 million. It also has refreshed its board, including industry veterans and a new chief scientific adviser.
Oncology drug developer Chimeric Therapeutics (ASX:CHM) was up 20% in April. The company announced that Emory Winship Cancer Institute in Atlanta was open to enrol patients in the phase 1/2 multi-centre clinical trial (NCT06055439) for CHM CDH17 cell therapy.
The phase 1/2 trial is a two-stage study designed to determine a recommended phase II dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs).
Imricor Medical Systems (ASX:IMR) also had a strong month, up 17.4% after positive news including launching its pivotal European clinical trial for ventricular tachycardia (VISABL-VT) – marking a series of world-first milestones – and securing CE Mark certification for its Advantage-MR system under the European Union’s new Medical Device Regulation (MDR).
Imricor is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively.
Health-imaging stock ProMedicus (ASX:PME) was up 14.8% in April. The company announced owned US subsidiary Visage Imaging, Inc. had signed a multi-year research collaboration deal with UCSF.
"I think ProMedicus just got oversold and it went down to around $150 at one point from just shy of $300," Wilkie said.
"These sorts of quality stocks always come back to the fore."
At Stockhead, we tell it like it is. While EBR Systems, Orthocell, Neuroscientific Biopharmaceuticals and Imricor Medical Systems are Stockhead advertisers, the companies did not sponsor this article.
Originally published as ASX health April winners: Sector rises 2pc in stronger month for markets
Energy stocks crumble but XPON lights up the ASX
Westpac dragged the banks lower, oil giants slipped, but Qantas soared on cheaper fuel and XPON was up 300pc on acquisition news.
Biotech sector recover as US conditions stabilise
Global and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is subsiding.
Break it Down: New World Resources
Tylah Tully digs into a New World Resources copper collection now significantly upgraded in both confidence and tonnage.
Break it Down: Rox Resources
Rox Resources has raised $40 million in a share purchase plan to advance its Youanmi project toward development.
ASX dips in early trade despite global tailwinds
The ASX looks to be ending its streak of wins today, down more than 0.2pc in early trading.
Guy on Rocks: Koonenberry Gold
Host Guy Le Page puts gold developer and explorer Koonenberry Gold under the microscope as the yellow metal trades ever higher.